ITGAX and neoplasm: Our data suggest that modulation of GCSF signaling in tumor-bearing mice diminishes aberrant STAT3-induced development and activation of immunosuppressive myeloid cells and boosts the frequency of immune-stimulatory cells such as cDC1s and CD11c+/MHCII+ MFs.